

NYMOX PHARMACEUTICAL CORP  
 Form 6-K  
 September 24, 2004

**FORM 6-K**

SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

**Report of Foreign Issuer  
 Pursuant to Rule 13a-16 or 15d-16  
 under the Securities Exchange Act of 1934**

September 24, 2004

Commission File Number: 001-12033

**Nymox Pharmaceutical Corporation**

9900 Cavendish Blvd., St. Laurent, QC, Canada, H4M 2V2

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If  Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

82-\_\_\_\_\_

The Company is providing a summary of the shares reported purchased by current directors and officers of the Company since the December 20, 2000 announcement of the director's and management's intention to purchase the Company's shares on the open market.

As of September 21, 2000, the following officers and directors have reported total purchases of Nymox Pharmaceutical Corporation stock amounting to 230,475 shares. They have sold no Nymox shares during that period.

**Nymox Shares Purchased by Current Directors and Officers Since December 20, 2000**

	<b>Michael Sonnenreich</b>	<b>Walter von Wartburg</b>	<b>Paul Averback</b>	<b>Hans Black</b>	<b>Jack Gemmell</b>	<b>Michael Munzar</b>
<b>Shares Owned and Controlled</b>						
Total Holdings 12/20/2000	10,000	12,000	13,094,395	10,000	0	31,325
	91,650	82,000	13,115,395	30,000	12,725	56,425

Edgar Filing: NYMOX PHARMACEUTICAL CORP - Form 6-K

	Michael Sonnenreich	Walter von Wartburg	Paul Averback	Hans Black	Jack Gemmell	Michael Munzar
Total Holdings 09/21/2004						
Total Sales since 12/20/2000	0	0	0	0	0	0
Total Purchases since 12/20/2000	81,650	70,000	21,000	20,000	12,725	25,100
<b>Purchased since December 20, 2000</b>						
12/21/2000	5,000	20,000				
01/03/2001	5,000					
02/16/2001	10,000					
02/28/2001			1,500			
03/04/2001					175	
03/23/2001			1,000			
03/28/2001			500			
04/10/2001						2,600
04/18/2001			4,000			
06/28/2001		10,000				
08/28/2001	5,000					
09/04/2001					1,200	
10/04/2001					8,625	
02/05/2002					525	
06/13/2002	10,000					
07/31/2002	5,000					
08/14/2002	1,650					
09/11/2002	1,000					
10/02/2002	3,000					
01/27/2003	1,000					
03/19/2003	1,000					

Edgar Filing: NYMOX PHARMACEUTICAL CORP - Form 6-K

	Michael Sonnenreich	Walter von Wartburg	Paul Averback	Hans Black	Jack Gemmell	Michael Munzar
04/08/2003	2,000					
04/16/2003	6,000					
05/07/2003	1,000					
05/30/2003	2,000					
06/11/2003	1,000					
08/19/2003						2,000
08/21/2003			4,000			
08/27/2003		10,000				
09/08/2003	2,000					2,000
09/10/2003						3,000
09/12/2003						2,500
09/17/2003						2,500
09/29/2003						2,000
10/01/2003						2,000
10/02/2003						150
10/03/2003						2,700
10/07/2003						2,650
10/20/2003						1,000
10/23/2003			10,000			
10/28/2003				8,000		
11/05/2004				2,000		
01/26/2004	1,000					
02/20/2004	3,000					
03/02/2004					2,200	
03/10/2004	5,000					
04/29/2004		20,000				

Edgar Filing: NYMOX PHARMACEUTICAL CORP - Form 6-K

05/04/2004	5,000					
06/08/2004	3,000			10,000		
06/09/2004	1,000					
06/14/2004	1,000					
08/12/2004	1,000					
08/24/2004		10,000				
<b>Total</b>	<b>81,650</b>	<b>70,000</b>	<b>21,000</b>	<b>20,000</b>	<b>12,725</b>	<b>25,100</b>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION  
(Registrant)

By: /s/ Paul Averbach  
Paul Averbach  
President and Chief Executive Officer

Date: September 24, 2004